Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A Randomised, controlled, phase 2 trial - Ribas, A; Puzanov, I; Dummer, R (Lancet Oncol, 2015)
et al.